Health Reform Magnifies Payers' Invisible Place At The Licensing Table
This article was originally published in The Pink Sheet Daily
Report from Licensing Executives Society meeting: Survey shows many already have taken action oncomparative effectiveness.
You may also be interested in...
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets
If a bioequivalent version of the clot buster launches in France, Sanofi is preparing to roll out its own generic version of clopidogrel.
At our September 2009 Pharmaceutical Strategic Alliances meeting, a recurring theme concerned the growing importance of factoring reimbursement hurdles into drug development decisions. Where does that start? In some cases, at Series A.